In patients who have discontinued idelalisib due to transaminitis, idelalisib should be
preferentially reassumed at lower dose than the initial one (e.g. 100 mg twice daily). when a
return to the basal ALT values occurs.
References
1. Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with
idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779-2786.
2. de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity
associated with ibrutinib and idelalisib: a practical approach. Haematologica.
2017;102(10):1629-1639.
3. Flinn IW, O'Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically
active in advanced hematologic malignancies. Blood. 2018;131(8):877-887.Forbes SG, Blood
2015; 3357-3359;
4. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent
lymphoma. N Engl J Med. 2014;370(11):1008-1018.
5. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8:48-54.
6. Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic
lymphocytic leukemia causes frequent immunemediated hepatotoxicity. Blood.
2016;128(2):195-203.
7. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological
modifier therapies: current concepts, management strategies, and future directions.
Gastroenterology. 2017;152(6):1297-1309.
8. Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA. Idelalisib-associated
enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg
Pathol. 2015;39(12):1653-1660
9. O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve
older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686-2694.Persico
M, Hepatology 2018;67:48-55
10. Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis
C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology.
2018;67(1):48-55.
11. Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib
(ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis
in patient subpopulations with Del(17p) and other adverse prognostic factors. Blood. 2014;124.
Abstract 330Smith S, Blood 124(21) abstract 3091A
12. Smith SM, Pitcher B, Jung SH, et al. Unexpected and serious toxicity observed with combined
idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: alliance A051201
and A051202. Blood. 2014;124. Abstract 3091
13. Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in
patients receiving cancer treatment: a prospective observational study. Hepatology.
2018;67(1):36-47.
14. Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14
patients. Am J Surg Pathol. 2015;39(12): 1661-1667.
15. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with
bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic
leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2017;18(3):297-311.